Impilo is a Nordic investment company focused solely on investments in companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Our starting point is that our portfolio companies must contribute to a positive and sustainable development of the communities and markets in which they operate in order to remain successful in the long term. This is a conviction that is embedded in our investment strategy since it necessitates a deeper understanding and reduces risks. This way, Impilo invests in people’s opportunities to enjoy healthier lives in the future.
Location: Sweden, Stockholm
Employees: 11-50
Founded date: 2017
Investment Type: Venture Capital
Portfolio 10
| Date | Name | Website | Total Raised | Location |
| 26.01.2021 | Scantox | scantox.com | - | Denmark, R... |
| 20.01.2021 | Mallax Pha... | mallaxpharma.com | - | Sweden, St... |
| - | Humana AB | humana.se | - | Sweden, St... |
| - | NutraQ | nutraq.com | - | Norway, Os... |
| - | Immedica P... | immedica.com | $65M | Sweden |
| - | Euro Accid... | euroaccident.se | - | Sweden, St... |
| - | Ferrosan M... | ferrosanmedicaldevices.com | - | Denmark, C... |
| - | Cavidi | cavidi.se | $11.5M | Sweden, Up... |
| - | Apotek Hjä... | apotekhjartat.se | - | Sweden, So... |
| - | The Fertil... | thefertilitypartnership.com | - | United Kin... |
News 18
| Date | Title | Description |
| 16.09.2021 | Impilo has closed its second investment pool | Impilo AB, the Nordic investment company focused on healthcare investments, has secured new commitments from new and existing investors of SEK 6bn (EUR 590m) and significantly exceeding its target amount. The capital raised enables new plat... |
| 01.07.2021 | Mallax acquires Sana Pharma Medical and creates a new Nordic pharmaceutical platform | Mallax Pharmaceuticals AB (”Mallax”) has acquired Sana Pharma Medical AS (”SPM” or the “Company”) and creates a new Nordic pharmaceutical platform. |
| 23.06.2021 | Impilo’s divestment of NutraQ to Orkla completed | On 15 June 2021, the sale of NutraQ to Orkla Health was completed after approval from all relevant competition authorities. NutraQ is a leading supplier of subscription-based health and wellness products in the Nordic region. The company wa... |
| 22.03.2021 | Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East | Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, and Immedica Pharma AB (Immedica) today announc... |
| 20.01.2021 | Impilo Acquires Scantox A/S, a Leading Danish Pre-Clinical Contract Research Organization | Today, the Danish pre-clinical contract research organization (“CRO”), Scantox A/S (“Scantox” or the “Company”) announced that it has been acquired by the leading Nordic healthcare investment company, Impilo, together with the management te... |
| 04.01.2021 | Immedica and WinHealth enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries | Immedica Pharma AB and Hongkong WinHealth Pharma Group CO., Ltd, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering t... |
| 15.12.2020 | Impilo and Anders Larnholt form a partnership to create a new pan‐European pharmaceutical platform | Impilo is pleased to have partnered with Anders Larnholt, an experienced pharma and healthcare executive, to create a new platform; Mallax Pharmaceuticals AB (“Mallax”). Mallax was founded in Sweden, with the aim of building a company with ... |
| 06.11.2020 | Immedica acquires the rights for Ravicti® and Buphenyl® for Japan from Horizon Therapeutics plc. | Immedica today announces that it has acquired the rights for the products Buphenyl® (sodium phenylbutyrate) and Ravicti® (glycerol phenylbutyrate) indicated for the treatment of Urea Cycle Disorders (UCD), in Japan from Horizon Therapeutics... |
| 29.04.2020 | PharmaMar signs an agreement with Immedica | PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin in Eastern Europe, the UK, Ireland, the Nordic countries and some Middle Eastern countries |
| 19.11.2019 | The Swedish Financial Supervisory Authority has approved the consortium of investors arranged by Impilo as new owners of Euro Accident Livförsäkring | - |
Show more
Mentions in press and media 33
| Date | Title | Description |
| 25.08.2026 | Immedica receives Orphan Drug Designation for pegzilarginase in Japan | Immedica receives Orphan Drug Designation for pegzilarginase in Japan Tue, Aug 25, 2026 11:00 CET Report this content STOCKHOLM, Sweden, August 25, 2026 - Immedica announces that Japan's Ministry of Health, Labor and Welfare (MHLW) has gran... |
| 03.08.2026 | Zepzelca® (lurbinectedin) in combination with atezolizumab approved as first-line maintenance therapy for extensive-stage small cell lung cancer in Qatar | Zepzelca® (lurbinectedin) in combination with atezolizumab approved as first-line maintenance therapy for extensive-stage small cell lung cancer in Qatar Mon, Aug 03, 2026 10:30 CET Report this content Stockholm, Sweden, August 3, 2026 – Im... |
| 29.06.2026 | AMBEA AB ( PUBL ) ANNOUNCES A RECOMMENDED PUBLIC OFFER TO THE SHAREHOLDERS OF HUMANA AB TO TENDER ALL THEIR SHARES IN HUMANA AB, AIMING TO COMBINE THE COMPANIES | AMBEA AB ( PUBL ) ANNOUNCES A RECOMMENDED PUBLIC OFFER TO THE SHAREHOLDERS OF HUMANA AB TO TENDER ALL THEIR SHARES IN HUMANA AB, AIMING TO COMBINE THE COMPANIES Mon, Jun 29, 2026 07:00 CET Report this content This press release does not con... |
| 23.06.2026 | Immedica announces marketing authorization approval in the UAE for Ztalmy® (ganaxolone) for CDKL5 deficiency disorder | Immedica announces marketing authorization approval in the UAE for Ztalmy® (ganaxolone) for CDKL5 deficiency disorder Tue, Jun 23, 2026 08:00 CET Report this content Stockholm, Sweden, June 23, 2026 – Immedica today announced that the Emira... |
| 18.05.2026 | Immedica announces sale of priority review voucher for USD 200 million | Immedica announces sale of priority review voucher for USD 200 million Mon, May 18, 2026 16:00 CET Report this content STOCKHOLM, Sweden, May 18, 2026 - Immedica Pharma announced today that it has completed the sale of its priority review v... |
| 08.05.2026 | Efmody® (modified-release hydrocortisone) receives MHRA approval for adrenal insufficiency in the UK | Efmody® (modified-release hydrocortisone) receives MHRA approval for adrenal insufficiency in the UK Fri, May 08, 2026 11:00 CET Report this content Stockholm, Sweden – May 8, 2026 - Immedica Pharma AB is pleased to announce that the UK Med... |
| 31.10.2025 | Immedica submits New Drug Submission (NDS) for Loargys® (pegzilarginase) to Health Canada | Immedica submits New Drug Submission (NDS) for Loargys® (pegzilarginase) to Health Canada Fri, Oct 31, 2025 12:00 CET Report this content Stockholm, Sweden, October 31, 2025 – Immedica today announced that the submitted New Drug Submission ... |
| 22.10.2025 | Impilo acquires Oticon Medical from Demant | Impilo acquires Oticon Medical from Demant Wed, Oct 22, 2025 12:32 CET Report this content Stockholm, 2025-10-22 - Impilo is pleased to announce that it has agreed to acquire Oticon Medical, a global leader in bone-anchored hearing solution... |
| 01.10.2025 | Immedica and Innovative Medicines Group enter agreement on Loargys® (pegzilarginase) in Latin America | Immedica and Innovative Medicines Group enter agreement on Loargys® (pegzilarginase) in Latin America Wed, Oct 01, 2025 11:00 CET Report this content Stockholm, Sweden, October 1, 2025 – Immedica has entered into an agreement with Innovativ... |
| 24.09.2025 | The Nomination Committee for Humana AB's 2026 AGM has been constituted | The Nomination Committee for Humana AB's 2026 AGM has been constituted Wed, Sep 24, 2025 15:43 CET Report this content The members of the Nomination Committee for Humana AB’s Annual General Meeting in 2026 have now been appointed. According... |
Show more